Lead Product(s): Monoclonal-bispecific Antibody-based Therapeutics
Therapeutic Area: Hematology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Novo Nordisk
Deal Size: $55.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing July 22, 2021
Proceeds from the financing will be used to progress the Company's promising pipeline of monoclonal and bispecific antibody-based therapeutics into later stages of development.